Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,330 total articles

Infrastructure Monitoring and Control Provider Acorn to Webcast Investor Presentation at Planet MicroCap Las Vegas Powered by MicroCapClub Conference Wed. June 17 at 12:30 PT

Infrastructure Monitoring and Control Provider Acorn to Webcast Investor Presentation at Planet MicroCap Las Vegas Powered by MicroCapClub Conference Wed. June 17 at 12:30 PT

Acorn Energy, Inc., a Nasdaq-listed company specializing in remote monitoring and control for critical infrastructure, announced a webcast of its investor presentation at the Planet MicroCap Las Vegas 2026 conference. The company reported 11.7% growth in Q1 2026 monitoring revenue to $5.7 million (LTM), with a strong gross margin of 78%. Acorn is e…

Applied Digital Announces Proposed Offering of $1.59 Billion of Senior Secured Notes to fund the Fourth Building at Polaris Forge 1

Applied Digital Announces Proposed Offering of $1.59 Billion of Senior Secured Notes to fund the Fourth Building at Polaris Forge 1

Applied Digital Corporation announced a proposed private offering of $1.59 billion in senior secured notes due 2031 to fund the construction of its fourth building at Polaris Forge 1, its AI Factory campus in Ellendale, North Dakota. The proceeds will also be used to repay a bridge loan, fund debt service reserves, and cover transaction expenses. T…

VEON Appoints Serkan Ozturk as Chief of Staff & Strategy Officer

VEON Appoints Serkan Ozturk as Chief of Staff & Strategy Officer

VEON Ltd. announces the appointment of Serkan Ozturk as Chief of Staff & Strategy Officer to strengthen leadership and support execution of strategic priorities. Serkan, joining the leadership team, brings extensive experience in strategy, transformation, and operational execution, aiming to enhance alignment and delivery of key initiatives across …

VenHub Global Expands Autonomous Retail Platform into Florida

VenHub Global Expands Autonomous Retail Platform into Florida

VenHub Global, a NASDAQ-listed company specializing in fully autonomous Smart Store technology, announced its expansion into Florida with an initial deployment in Tampa Bay. This strategic move aims to capitalize on Florida's strong retail growth, population increase, and labor shortages by enabling local operators to launch autonomous retail locat…

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics announced that its clinical-stage drug elraglusib will be evaluated in the landmark European BEACON2 multi-arm, multi-stage Phase 1/2 trial for children with relapsed and refractory neuroblastoma. Elraglusib will be assessed in combination with dinutuximab beta and chemotherapy to determine safety and optimal dosing. The trial …

ZenaTech Added to Russell 3000® Index, Marking Major Milestone in Company's Growth and Market Recognition

ZenaTech Added to Russell 3000® Index, Marking Major Milestone in Company's Growth and Market Recognition

ZenaTech, a company specializing in AI-driven drone platforms and enterprise SaaS solutions, has been added to the Russell 3000® Index effective June 29, 2026. This milestone reflects the company's expanding market capitalization and growth, expected to increase visibility among institutional investors and bolster investor confidence in its AI dron…

BitFuFu Announces May 2026 Bitcoin Production and Operational Updates

BitFuFu Announces May 2026 Bitcoin Production and Operational Updates

BitFuFu Inc. announced its May 2026 Bitcoin production and operational results, highlighting a 22.1% month-over-month increase in Bitcoin production to 177 BTC. The company significantly shifted its production mix by nearly tripling self-mining output to 90 BTC, reflecting a strategic decision to accumulate Bitcoin holdings amid favorable market co…

PureCycle, Innovia Films Partner to Successfully Produce White, Cavitated BOPP Film Using PureFive Choice™ Recycled Polypropylene

PureCycle, Innovia Films Partner to Successfully Produce White, Cavitated BOPP Film Using PureFive Choice™ Recycled Polypropylene

PureCycle Technologies announced the successful production and trial evaluation of white, cavitated biaxially oriented polypropylene (BOPP) film using its PureFive Choice™ recycled polypropylene resin, in partnership with Innovia Films. This film contains more than 40% post-consumer recycled content and meets performance and appearance standards im…

Applied Materials Announces Cash Dividend

Applied Materials Announces Cash Dividend

Applied Materials announced a quarterly cash dividend of $0.53 per share payable on September 10, 2026, continuing its pattern of dividend growth with nine consecutive years of increases. The company has increased dividends at an 18% compound annual growth rate over the past decade and distributed a significant portion of free cash flow to sharehol…

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

BrainsWay Ltd. presented new 12-month durability data demonstrating that their FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol provides sustained remission in over 80% of Major Depressive Disorder patients, significantly improving functionality and quality of life with fewer clinic visits compared to standa…

Creative Realities added to membership of Russell 3000® Index

Creative Realities added to membership of Russell 3000® Index

Creative Realities, Inc. announced its inclusion in the Russell 3000 Index effective June 29, 2026, reflecting its growing market capitalization and integration of Cineplex Digital Media. This inclusion is expected to broaden its institutional investor base and affirm its growth strategy in digital signage and AdTech sectors.

CVRx Announces Chief Financial Officer Transition

CVRx Announces Chief Financial Officer Transition

CVRx, Inc., a NASDAQ-listed medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced that CFO Jared Oasheim will step down to pursue other opportunities but will stay until a successor is appointed and remain an advisor through February 2027. Oasheim has been with the company since 2015 and helped lead…

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics announced positive topline Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in patients with myasthenia gravis (MG), showing significant clinical improvement and good tolerability. The company also initiated a potentially registration-directed Phase 2 trial to evaluate BRIUMVI as maintenance therapy following induction wi…

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Corvus Pharmaceuticals announced a $5 million investment as part of a $13.5 million financing round for its collaboration partner Angel Pharmaceuticals. The funding will support ongoing and upcoming Phase 1b/2 clinical trials of soquelitinib for atopic dermatitis and asthma in China. Corvus retains a significant ownership stake in Angel Pharma and …

QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing

QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing

QTREX Quantum Ltd. announced receiving approximately $1 million from the Israel Innovation Authority to develop a specialized dielectric material optimized for high-density, low-loss RF signal routing in superconducting quantum computers. This development aims to overcome the key scaling challenges in quantum hardware connectivity by integrating ma…

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced successful alignment with the U.S. FDA during the End-of-Phase 2 meeting, agreeing on key aspects of the planned Phase 3 clinical trial for ATH434 in treating Multiple System Atrophy (MSA). The FDA approved the study population, dosing regimen, treatment duration, primary and key secondary endpoints, and statistical …

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics has announced a strategic licensing agreement with WestGene Biopharma to combine Cartesian's mRNA CAR-T payload technology with WestGene's targeted lipid nanoparticle platform for in vivo delivery. The partnership aims to initiate Phase 1 clinical trials in the second half of 2026 for generalized myasthenia gravis patients, w…

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics announced the dosing of the first participant in the Phase 1 trial of KT-485, an oral IRAK4 degrader for immuno-inflammatory diseases, conducted by partner Sanofi. This milestone triggered a $20 million payment from Sanofi to Kymera under their collaboration, which includes potential total milestones of up to $975 million. The t…